SAFC Strengthens Biopharmaceutical Position with Innovations to Established CHOZN Portfolio
Sigma-Aldrich Corp. has announced that SAFC Commercial, its custom manufacturing services business unit, has engineered additional traits into its CHOZN Platform cell line, increasing the utility of the CHOZN portfolio of products and services.
Two novel host cell lines have been added to the CHOZN portfolio, yielded through SAFC’s continuous research and development. The first of these lines is the CHOZN GS-/- host trait stacked with a knockout of the MGAT1 gene function that results in early termination of the N-glycan pathway and enables the expression of recombinant proteins with homogeneous high Man5 glycan profiles. This is useful for protein crystallography studies, as well as for the expression of biotherapeutics that target mannose receptors.
The second novel cell line is the CHOZN GS-/- host trait stacked with knockouts of the CMAH and GGTA gene sequences. The knockout of the function of these two genes enables the expression of recombinant proteins that do not contain the antigenic alpha-gal and Neu5Gc moieties on the glycan structures and makes them capable of producing potentially safer therapeutic proteins. These two newly engineered CHO host cells, as well as the parental CHO-K1 cell line, are now commercially available from SAFC as custom products.
“The additional traits and unique combination of the CHOZN platform and media/feed optimisation services provide a best-in-class offer, with continuous advances to the customer,” said Kevin Gutshall, Senior Manager for Marketing and Commercial Licensing. “SAFC’s CHOZN Portfolio, in combination with Sigma-Aldrich’s robust intellectual property on the Zinc Finger Nuclease (ZFN) technology, provides CHOZN customers with a seamless gateway from development through commercialisation.”
The CHOZN portfolio consists of the CHOZN Platform (CHOZN GS-/- CHO cell line and an optimised set of cGMP-produced, chemically defined (CD) media and feeds), additional CHOZN ZFN-modified cell lines, ZFN reagents, and customisation options including cell line and media development projects. Powered by Sigma-Aldrich’s CompoZr ZFN technology, SAFC’s cGMP-produced and tested CHOZN GS-/- cell line was the first commercially available glutamine synthetase (GS) knockout CHO line on the market. The CHOZN GS-/- platform provides a GS-/- cell line that enables streamlined selection, identification and scale-up of high-producing manufacturing clones, saving weeks of development time. In addition, the lean CD media and feed system allows for tunable product quality.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance